(5-苯基-1,3-恶唑-4-基)甲醇 | 352018-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (5-苯基-1,3-恶唑-4-基)甲醇
• 中文别名: 5-苯基-1,3-恶唑-4-甲醇
• 英文名称: (5-phenyloxazol-4-yl)methanol
• 英文别名: (5-Phenyl-1,3-oxazol-4-yl)methanol
• CAS: 352018-88-3
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: LVHWTAMRDRDXJP-UHFFFAOYSA-N

物化性质

• 熔点：
  95 °C
• 沸点：
  366.6±30.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2934999090
• 储存条件：
  2-8°C

SDS

Name:	(5-Phenyl-1 3-oxazol-4-yl)methanol 95+% Material Safety Data Sheet
Synonym:
CAS:	352018-88-3

Section 1 - Chemical Product MSDS Name:(5-Phenyl-1 3-oxazol-4-yl)methanol 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
352018-88-3	(5-Phenyl-1,3-oxazol-4-yl)methanol	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 352018-88-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 94 - 95 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9NO2
Molecular Weight: 175.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 352018-88-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(5-Phenyl-1,3-oxazol-4-yl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 352018-88-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 352018-88-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 352018-88-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (5-苯基-1,3-恶唑-4-基)甲醇 在 manganese(IV) oxide 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成 (z)-1-Acetyl-3-((5-phenyloxazol-4-yl)methylene)piperazine-2,5-dione
  参考文献：
  名称：

  基于共晶结构的新型抗肿瘤药物普那布林衍生物的设计、合成及构效关系研究

  摘要：

  普那布林是一种源自海洋天然产物的2, 5-二酮哌嗪型微管蛋白抑制剂，目前正在进行治疗非小细胞肺癌（NSCLC）和化疗引起的中性粒细胞减少症（CIN）的III期临床试验。为了获得具有更高生物活性的新型2,5-二酮哌嗪衍生物，我们基于化合物1与微管蛋白的共晶结构，设计合成了C环上两个系列的37个普那布林衍生物。使用 NMR 和 HRMS 对其结构进行了表征。采用MTT法在肺癌细胞系NCI-H460上对所有化合物进行体外筛选，并在BxPC-3和HT-29细胞中进一步筛选活性较好的化合物。化合物16c （IC 50 = 2.0，NCI-H460；IC 50 = 1.2 nM，BxPC-3；IC 50 = 1.97 nM，HT-29）和26r （IC 50 = 0.96，NCI-H460；IC 50 = 0.66 nM） ，BxPC-3；IC 50 = 0.61 nM，HT-29）具有最佳活性。化合

  DOI：

  10.1007/s11030-024-10835-7
• 作为产物：
  描述：

  5-苯基噁唑-4-羧酸乙酯 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 以100 %的产率得到(5-苯基-1,3-恶唑-4-基)甲醇
  参考文献：
  名称：

  铜催化N-羟基琥珀酰亚胺酯与异氰基乙酸酯的[3+2]环加成反应合成4,5-二取代恶唑

  摘要：

  描述了铜催化的N-羟基琥珀酰亚胺酯与异氰酸根乙酸酯的环加成反应。以中高产率获得了一系列 4,5-二取代恶唑化合物，包括衍生自天然脂肪酸、药物、氨基酸和肽的化合物。探索了衍生化反应。讨论了反应机理。

  DOI：

  10.1021/acs.joc.2c03084

文献信息

• SUBSTITUTED PYRAZOLE DERIVATIVES
  申请人：ITO Mitsuhiro

  公开号：US20090270359A1

  公开（公告）日：2009-10-29

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供一种新型吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供一种由下式表示的化合物(I′)：其中R1是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R2是苯基，带有氰基（苯基可能还有除氰基之外的取代基）；R3是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R4是可选地带有取代基的环状基团；X是亚甲基，可选地带有取代基，或CO，或其盐。
• Substituted arylalkanoic acid derivatives and use thereof
  申请人：Shoda Motoshi

  公开号：US20070213333A1

  公开（公告）日：2007-09-13

  A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C 2 to C 6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）：[在公式中，Link代表饱和或不饱和的直链碳氢链，其具有1至3个碳原子，C2至C6在芳环（E）中独立地表示构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或被Zx取代的碳原子，Zx代表饱和的烷基基团，其具有1至4个碳原子等，Rs代表-D-Rx等，D代表单键，氧原子等，Rx代表饱和的烷基基团，其具有3至8个碳原子等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子，具有1至4个碳原子的低烷基基团等]或其盐。提供了一种具有前列腺素生成抑制作用和白三烯生成抑制作用的化合物。
• SUBSTITUTED PYRAZOLE DERIVATIVE
  申请人：Ito Mitsuhiro

  公开号：US20100227846A1

  公开（公告）日：2010-09-09

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供了一种新的吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供了一种由式(I')表示的化合物，其中R1是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团; R2是具有氰基的苯基（苯基可以进一步具有除氰基以外的取代基）; R3是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团; R4是可选地具有取代基的环状基团; X是可选地具有取代基的亚甲基，或CO，或其盐。
• Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
  申请人：Amgen Inc.

  公开号：US20130150339A1

  公开（公告）日：2013-06-13

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物或其药学上可接受的盐，它们是电压门控钠通道抑制剂，特别是Nav 1.7的抑制剂。这些化合物用于治疗可通过钠通道抑制治疗的疾病，如疼痛性疾病。同时提供了含有本发明化合物的药物组合物。
• DMAP-Catalyzed Regel-Type Direct C-2 (Hetero)Aroylation of Oxazoles and Thiazoles Derivatives with Acid Chlorides
  作者：Christophe Hoarau、Pierrik Lassalas、Francis Marsais

  DOI：10.1055/s-0033-1339858

  日期：——

  A Regel-type transition-metal-free direct C-2 aroylation of (benzo)oxazoles, (benzo)thiazoles and 1,3,4-oxadiazoles with acid chlorides catalyzed by N,N-dimethyl-4-aminopyridine (DMAP) is described. This methodology is effective with several aroyl and heteroaroyl chlorides affording the corresponding 2-ketoazoles in moderate to excellent yields.